Alpha 2.0
Login Register
» Articles » PMID: 21350358

Durability and Safety of a Novel Salvage Therapy in R5-tropic HIV-infected Patients: Maraviroc, Raltegravir, Etravirine

Overview
Journal J Acquir Immune Defic Syndr
Specialty Infectious Diseases
Date 2011 Feb 26
PMID 21350358
Citations 5
Authors
Silvia Nozza
Laura Galli
Alba Bigoloni
Gianotti Nicola
Manuela Pogliaghi
Francesca Cossarini
Stefania Salpietro
Andrea Galli
Liviana Della Torre
Giuseppe Tambussi
Adriano Lazzarin
Antonella Castagna
Affiliations
Soon will be listed here.
Citing Articles

Heavily treatment-experienced patients with HIV: are new mechanisms of action enough?.

Brizzi M, Cable T, Patel D, Williams K, Adjei Z, Fichtenbaum C J Int Med Res. 2024; 52(12):3000605241301883.

PMID: 39633602 PMC: 11618923. DOI: 10.1177/03000605241301883.

Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice.

Potard V, Reynes J, Ferry T, Aubin C, Finkielsztejn L, Yazdanpanah Y PLoS One. 2015; 10(12):e0144746.

PMID: 26714012 PMC: 4695083. DOI: 10.1371/journal.pone.0144746.

Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.

Lucas G, Ross M, Stock P, Shlipak M, Wyatt C, Gupta S Clin Infect Dis. 2014; 59(9):e96-138.

PMID: 25234519 PMC: 4271038. DOI: 10.1093/cid/ciu617.

Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.

Achhra A, Boyd M, Law M, Matthews G, Kelleher A, Cooper D PLoS One. 2014; 9(6):e99530.

PMID: 24968324 PMC: 4072535. DOI: 10.1371/journal.pone.0099530.

Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature.

Achhra A, Boyd M AIDS Res Ther. 2013; 10(1):33.

PMID: 24330617 PMC: 3874614. DOI: 10.1186/1742-6405-10-33.